clinical trial · NCT04161898
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
AbbVie·phase3·active not recruiting·n = 56
Takayasu Arteritis (TAK)UpadacitinibPlacebo for UpadacitinibPrednisolone
brief summary
The main objective of this study is to evaluate the efficacy of upadacitinib in combination with a corticosteroid taper regimen compared to placebo in combination with a corticosteroid taper regimen.
started
Feb 4, 2020
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
Feb 18, 2026
official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol